

**S1 Table: Average cumulative dose (DDD) of drugs classified as Other DMARDs, dispensed to patients with rheumatoid and seropositive arthritis one year before and after the first dispense of LDN.**

	LDN exposure	Dispensed drugs (DDD)		Difference (DDD)		
		Before	After	Mean	95% CI	p
<b>All other DMARDs</b>	LDN x 1	159.0	173.1	14.1	(-26.8 to 55.1)	0.500
	LDN x 2-3	149.1	201.2	52.1	(4.3 to 99.9)	0.036
	LDN x 4+	148.1	135.1	-13.0	(-37.5 to 11.4)	0.297
<b>Antimalarials</b>	LDN x 1	49.5	49.5	0.0	(-13.5 to 13.5)	1.000
	LDN x 2-3	51.2	65.3	14.1	(-3.5 to 31.8)	0.120
	LDN x 4+	43.9	40.6	-3.3	(-15.6 to 8.9)	0.594
<b>Methotrexate</b>	LDN x 1	93.2	98.8	5.6	(-19.2 to 30.4)	0.657
	LDN x 2-3	94.2	121.9	27.7	(-0.7 to 56)	0.059
	LDN x 4+	84.8	75.5	-9.3	(-22.1 to 3.6)	0.158
<b>Aminosalicylates</b>	LDN x 1	13.0	14.3	1.4	(-2.6 to 5.4)	0.505
	LDN x 2-3	3.0	3.3	0.3	(-0.8 to 1.5)	0.567
	LDN x 4+	12.8	12.9	0.1	(-7.2 to 7.4)	0.973
<b>Leflunomide</b>	LDN x 1	3.3	10.5	7.1	(-3.7 to 18)	0.198
	LDN x 2-3	0.7	10.7	10.0	(-2.2 to 22.2)	0.112
	LDN x 4+	6.7	6.1	-0.6	(-3.4 to 2.3)	0.707

LDN, low dose naltrexone. DDD, defined daily dose. DMARD, disease modifying antirheumatic drug. Three groups based on number of LDN dispenses: LDN ×1 (*N* = 164) collected LDN once, LDN ×2–3 (*N* = 115) two or three times and LDN ×4+ (*N* = 224) four or more times. There were no users of anakinra, azathioprine, ciclosporine, mercaptopurine, rituximab, tacrolimus, and tocilizumab neither before nor after starting LDN